One noteworthy ongoing study, NeoADURA, is the first phase III multicenter clinical trial specifically investigating neoadjuvant therapy for patients with resectable stage II to IIIB N2 NSCLC with EGFR mutations [44]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.